Top 5 Most-Read Dermatology Content of 2025

The top 5 most-read dermatology content of 2025 on AJMC.com included innovative advances from artificial intelligence (AI)–enabled wearable devices for atopic dermatitis (AD) to new FDA-approved therapies and novel treatments to treat rare dermatological diseases like bullous pemphigoid and complex disorders like vitiligo.

Here are our top 5 dermatology pieces of 2025, and you can click here to see more of our dermatology coverage.

5. Nicotinamide Reduces New Skin Cancer Risk in Large Veteran Study

Nicotinamide, a derivative of vitamin B3, may offer meaningful protection against skin cancer. Using the health records of 33,000 veterans with a history of skin cancer, researchers found that oral nicotinamide was associated with a significant reduction in new skin cancers. Nicotinamide has been researched for its ability to support DNA repair and reduce ultraviolet-induced immune suppression. The efficacy demonstrated in the phase 3 trial could encourage dermatologists to recommend it to patients, but further research is still needed to assess the long-term benefits and real-world impact.

Read the full article

4. AI-Enabled Wearable Sensor Reduces Scratching in Atopic Dermatitis

A new study found that an AI-enabled wearable sensor may reduce nocturnal scratching in patients with AD and self-reported moderate or severe scratching behaviors. The flexible wearable device is mounted on the dorsal hand using an AI-driven scratch algorithm that demonstrated high sensitivity and specificity in adult patients with AD when detecting nocturnal scratching when compared against infrared video recordings. Although the study population was limited in size, researchers are aiming to expand it to include pediatric patients.

Read the full article.

3. FDA Expands Dupilumab Approval as First New Biologic for Bullous Pemphigoid

The FDA approved dupilumab to treat bullous pemphigoid, a chronic relapsing disease that can cause intense itch and blisters, red skin, and painful chronic lesions. The expanded approval of the fully human monoclonal antibody was based on results from the LIBERTY-BP ADEPT phase 2 and 3 trial, which met both its primary and secondary end points. Sustained disease remission was achieved in 20% of patients receiving dupilimab at 36 weeks compared with 4% in those who received the placebo. There were no adverse events that led to death in the dupilumab group vs 2 in the placebo group. This approval further reinforces the safety of dupilumab, which has been approved for numerous other indications. 

Read the full article.

2. Future of Vitiligo Treatment: Emerging Therapies, Impact on Quality of Life

Vitiligo is a complex dermatologic disorder that affects patients' psychosocial well-being and quality of life, especially those with darker skin tones. However, emerging therapies, such as Janus kinase (JAK) inhibitors like FDA-approved ruxolitinib, and experimental treatments like simvastatin, afamelanotide, and metformin, show promise for improving regimen and symptom management. Novel approaches, including autophagy promotion and prostaglandin analogs, are also being explored. While these treatments offer hope for more targeted and effective care, further research is needed to establish their safety, efficacy, and optimal use.

Read the full article.

1. Hidradenitis Suppurativa: Advancing Treatment With Biologics

Hidradenitis suppurativa (HS) is a chronic, painful inflammatory skin condition often managed with biologics. Adalimumab, a tumor necrosis factor–α inhibitor, was FDA approved in 2015, and secukinumab, an IL-17A inhibitor, gained approval in 2023, both targeting moderate to severe HS. Treatment decisions must consider patient-specific factors such as age, comorbidities, and immunosuppression risks; also, loss of response to biologics is common, prompting therapeutic drug monitoring. Ongoing research is focused on optimizing biologic therapies and identifying individualized treatment strategies to improve long-term outcomes.

Read the full article.